Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now ...
FierceBiotech

AMRI RECEIVES NIH CONTRACT AWARD FOR THE FORMULATION DEVELOPMENT AND MANUFACTURE OF PRE-CLINICAL AND CLINICAL DRUG PRODUCT

ALBANY, N.Y., Jan. 19, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it received a 10-year federal contract award from the National Institutes of Health (NIH) for drug development and ...